F. J. Nunez

This paper identifies zotiraciclib as a therapeutic agent targeting IDH-mutant gliomas by disrupting mitochondrial function and inducing oxidative stress, leading to a clinical trial.

This study shows that H3.3-G34R mutations reprogram the tumor immune microenvironment in diffuse hemispheric gliomas, enhancing the efficacy of immune stimulatory gene therapy and leading to long-term survival in treated mice.

This paper identifies ZMYND8 as a gene epigenetically regulated by mIDH1 that promotes radioresistance in glioma cells, and shows its knockdown enhances radiosensitivity.

This paper describes a single-dose hybrid hAdV5-based vaccine that induces long-lasting immunity and broad neutralization against SARS-CoV-2 variants.

This study shows that FYN tyrosine kinase in glioma cells suppresses anti-glioma immune responses, and its inhibition reduces tumor growth and improves survival in immune-competent models.

This paper tests an immune-stimulatory gene therapy in a mouse model of DIPG, showing increased survival and anti-tumor immunity through adenoviral delivery of TK and Flt3L.

This study identifies the IDH-Tau-EGFR triad as a key factor in defining the neovascular landscape of diffuse gliomas by regulating mesenchymal differentiation and vascular microenvironment.